Hanan E Alatwi, Amnah A Alharbi, Rashid Mir, Othman R Alzahrani, Abdulrahman H Alessa, Yousef M Hawsawi, Mohammed Ali Arishi, Aziz Dhaher Albalawi
{"title":"沙特结直肠癌患者的全外显子组测序揭示了不同的突变模式和人群特异性致病变异。","authors":"Hanan E Alatwi, Amnah A Alharbi, Rashid Mir, Othman R Alzahrani, Abdulrahman H Alessa, Yousef M Hawsawi, Mohammed Ali Arishi, Aziz Dhaher Albalawi","doi":"10.3389/fonc.2025.1679528","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Colorectal cancer (CRC) shows significant inter-population heterogeneity in its genomic landscape, yet Middle Eastern populations are underrepresented in large-scale sequencing studies. This exploratory study aims to characterize somatic mutations and disrupted signaling pathways in Saudi Arabian CRC patients.</p><p><strong>Methods: </strong>We performed whole-exome sequencing (WES) on tumor DNA from 24 Saudi CRC patients. Somatic variants were identified and analyzed in a curated panel of cancer-related genes. Comparative analysis was conducted against The Cancer Genome Atlas colorectal cancer dataset (TCGA-COADREAD), and pathway enrichment analysis was performed.</p><p><strong>Results: </strong>Somatic variants were identified in 23 tumors, with recurrent mutations in <i>BRCA2</i> (61%), <i>TCF7L2</i> (52%), <i>EGFR</i> (43%), and <i>SOS1</i> (43%). Compared to TCGA-COADREAD, mutation frequencies were significantly higher in <i>BRCA2</i>, <i>EGFR</i>, <i>SLC25A5</i>, and <i>PIK3R2</i> (adjusted p < 0.0001). Among 258 total variants, 43% were novel, and 25 were classified as pathogenic, likely pathogenic, or deleterious, including 13 novel variants across nine genes. Pathway analysis revealed frequent disruptions in WNT/β-catenin (65%), homologous recombination (61%), PI3K (48%), and RTK/RAS (43%) signaling pathways.</p><p><strong>Conclusion: </strong>Our results reveal a distinct mutational profile in Saudi CRC patients, characterized by novel and enriched somatic variants affecting key oncogenic pathways. These findings underscore the necessity of including underrepresented populations in cancer genomics to support globally equitable precision oncology.</p>","PeriodicalId":12482,"journal":{"name":"Frontiers in Oncology","volume":"15 ","pages":"1679528"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540182/pdf/","citationCount":"0","resultStr":"{\"title\":\"Whole-exome sequencing in Saudi colorectal cancer patients reveals distinct mutational patterns and population specific pathogenic variants.\",\"authors\":\"Hanan E Alatwi, Amnah A Alharbi, Rashid Mir, Othman R Alzahrani, Abdulrahman H Alessa, Yousef M Hawsawi, Mohammed Ali Arishi, Aziz Dhaher Albalawi\",\"doi\":\"10.3389/fonc.2025.1679528\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Colorectal cancer (CRC) shows significant inter-population heterogeneity in its genomic landscape, yet Middle Eastern populations are underrepresented in large-scale sequencing studies. This exploratory study aims to characterize somatic mutations and disrupted signaling pathways in Saudi Arabian CRC patients.</p><p><strong>Methods: </strong>We performed whole-exome sequencing (WES) on tumor DNA from 24 Saudi CRC patients. Somatic variants were identified and analyzed in a curated panel of cancer-related genes. Comparative analysis was conducted against The Cancer Genome Atlas colorectal cancer dataset (TCGA-COADREAD), and pathway enrichment analysis was performed.</p><p><strong>Results: </strong>Somatic variants were identified in 23 tumors, with recurrent mutations in <i>BRCA2</i> (61%), <i>TCF7L2</i> (52%), <i>EGFR</i> (43%), and <i>SOS1</i> (43%). Compared to TCGA-COADREAD, mutation frequencies were significantly higher in <i>BRCA2</i>, <i>EGFR</i>, <i>SLC25A5</i>, and <i>PIK3R2</i> (adjusted p < 0.0001). Among 258 total variants, 43% were novel, and 25 were classified as pathogenic, likely pathogenic, or deleterious, including 13 novel variants across nine genes. Pathway analysis revealed frequent disruptions in WNT/β-catenin (65%), homologous recombination (61%), PI3K (48%), and RTK/RAS (43%) signaling pathways.</p><p><strong>Conclusion: </strong>Our results reveal a distinct mutational profile in Saudi CRC patients, characterized by novel and enriched somatic variants affecting key oncogenic pathways. These findings underscore the necessity of including underrepresented populations in cancer genomics to support globally equitable precision oncology.</p>\",\"PeriodicalId\":12482,\"journal\":{\"name\":\"Frontiers in Oncology\",\"volume\":\"15 \",\"pages\":\"1679528\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12540182/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fonc.2025.1679528\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fonc.2025.1679528","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:结直肠癌(CRC)在其基因组景观中显示出显著的人群间异质性,但中东人群在大规模测序研究中代表性不足。本探索性研究旨在表征沙特阿拉伯结直肠癌患者的体细胞突变和信号通路中断。方法:对24例沙特结直肠癌患者的肿瘤DNA进行全外显子组测序(WES)。体细胞变异在一个癌症相关基因的筛选小组中被识别和分析。与The Cancer Genome Atlas结直肠癌数据集(TCGA-COADREAD)进行对比分析,并进行途径富集分析。结果:在23个肿瘤中鉴定出体细胞变异,其中BRCA2(61%)、TCF7L2(52%)、EGFR(43%)和SOS1(43%)的复发突变。与TCGA-COADREAD相比,BRCA2、EGFR、SLC25A5和PIK3R2的突变频率显著高于TCGA-COADREAD(调整后p < 0.0001)。在258个变异中,43%是新变异,25个被归类为致病性、可能致病性或有害的,包括9个基因的13个新变异。通路分析显示WNT/β-catenin(65%)、同源重组(61%)、PI3K(48%)和RTK/RAS(43%)信号通路频繁中断。结论:我们的研究结果揭示了沙特结直肠癌患者的独特突变特征,其特征是影响关键致癌途径的新颖和丰富的体细胞变异。这些发现强调了在癌症基因组学中纳入代表性不足的人群以支持全球公平的精确肿瘤学的必要性。
Whole-exome sequencing in Saudi colorectal cancer patients reveals distinct mutational patterns and population specific pathogenic variants.
Background: Colorectal cancer (CRC) shows significant inter-population heterogeneity in its genomic landscape, yet Middle Eastern populations are underrepresented in large-scale sequencing studies. This exploratory study aims to characterize somatic mutations and disrupted signaling pathways in Saudi Arabian CRC patients.
Methods: We performed whole-exome sequencing (WES) on tumor DNA from 24 Saudi CRC patients. Somatic variants were identified and analyzed in a curated panel of cancer-related genes. Comparative analysis was conducted against The Cancer Genome Atlas colorectal cancer dataset (TCGA-COADREAD), and pathway enrichment analysis was performed.
Results: Somatic variants were identified in 23 tumors, with recurrent mutations in BRCA2 (61%), TCF7L2 (52%), EGFR (43%), and SOS1 (43%). Compared to TCGA-COADREAD, mutation frequencies were significantly higher in BRCA2, EGFR, SLC25A5, and PIK3R2 (adjusted p < 0.0001). Among 258 total variants, 43% were novel, and 25 were classified as pathogenic, likely pathogenic, or deleterious, including 13 novel variants across nine genes. Pathway analysis revealed frequent disruptions in WNT/β-catenin (65%), homologous recombination (61%), PI3K (48%), and RTK/RAS (43%) signaling pathways.
Conclusion: Our results reveal a distinct mutational profile in Saudi CRC patients, characterized by novel and enriched somatic variants affecting key oncogenic pathways. These findings underscore the necessity of including underrepresented populations in cancer genomics to support globally equitable precision oncology.
期刊介绍:
Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.